Blue Bird Corp Files Prospectus Supplement for Resale of 2.7M Shares

What Happened
Blue Bird Corporation (the “Company”) filed an 8‑K on October 1, 2026 to disclose a prospectus supplement to its automatic shelf registration statement on Form S-3 (File No. 333-284017). The supplement covers resale, from time to time, by a selling stockholder of up to 2,702,180 shares of the Company’s common stock that are issuable upon exchange, retraction or redemption (at the selling stockholder’s election) of non‑voting exchangeable shares of MB Exchangeco Inc. (“MB ExchangeCo”), an indirect wholly owned Canadian subsidiary. Those exchangeable shares were issued in connection with Blue Bird’s April 1, 2026 acquisition of the former joint-venture partner’s 50% interest in the Micro Bird joint venture. The 8‑K is being filed primarily to furnish the legal opinion of Smith, Gambrell & Russell, LLP regarding the validity of the common stock (attached as Exhibit 5.1).

Key Details

• Resale registration covers up to 2,702,180 shares of Blue Bird common stock.
• Prospectus supplement filed October 1, 2026 under Form S-3 (File No. 333-284017).
• Exchangeable shares were issued as part of the April 1, 2026 acquisition of the remaining 50% interest in the Micro Bird joint venture.
• Legal opinion from Smith, Gambrell & Russell, LLP on the validity of the common stock is included as Exhibit 5.1.

Why It Matters
This filing enables a selling stockholder to offer and resell common shares that may be issued when MB ExchangeCo exchangeable shares are converted or redeemed. For investors, that creates a potential source of additional shares entering the market over time, which can affect supply and liquidity. The attached legal opinion supports the legal validity of the shares being offered, but the filing does not report earnings, management changes, or new operating results—it is a disclosure about resale mechanics tied to the Micro Bird acquisition.